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Abstract

The role of circulating tumor cells (CTCs) as a marker for
disease progression in metastatic cancer is controversial.
The current review will serve to summarize the evidence on
CTCs as a marker of disease progression in patients with
metastatic breast cancer. The immunohistochemistry (IHC)based CellSearch® is the only FDA-approved isolation
technique for quantifying CTCs in patients with metastatic
breast cancer. We searched PubMed and Web of Knowledge
for clinical studies that assessed the prognostic and predictive
value of CTCs using IHC-based isolation.
The patient outcomes reported include median and Coxproportional hazard ratios for overall survival (OS) and
progression-free survival (PFS). All studies reported shorter
OS for CTC-positive patients versus CTC-negative. A subset
of the selected trials reported significant lower median
PFS for CTC-positive patients. The reported trials support
the utility of CTC enumeration for patient prognosis. But
further studies are required to determine the utility of CTC
enumeration for guiding patient therapy. There are three
clinical trials ongoing to test this hypothesis. These studies,
and others, will further establish the role of CTCs in clinical
practice. (J Patient-Centered Res Rev. 2014;1:85-92.)
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Introduction

Breast cancer is the leading non-skin cancer diagnosed in
females in the United States, with more than 200,000 new
cases reported per year.1 Metastatic breast cancer (MBC)
can present at initial diagnosis or after recurrence. While
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treatments for MBC are not considered curative, development
of targeted biologic therapies and chemotherapy have
significantly increased survivals.2,3 Current prognostic
factors for MBC include Eastern Cooperative Oncology
Group patient performance status, the site of metastatic
disease, the number of disease sites, estrogen receptor status,
progesterone receptor status, human epidermal growth
factor receptor-2 (HER2/neu) expression, progressionfree interval, prior adjuvant therapy, and prior therapy
for MBC.4-7 In addition to these initial tumor features,
various techniques are used to measure tumor response
or disease progression while on anticancer treatments.
These include various imaging modalities that detect site
of disease, quantify tumor volume,8,9 and detect glucose
uptake.10-13 Unfortunately, imaging studies fail to capture
tumor heterogeneity, are expensive and time consuming,
and because they are done sporadically, may not provide
timely detection of therapeutic resistance.14-16 Because of
these shortcomings, various assays have been developed
to measure blood-based biomarkers including CA15-3 and
CA27.29, carcinoembryonic antigen (CEA) and CA-125.17-19
However, only 50% to 60% of MBCs have a positive tumor
marker to follow, and prospective studies validating their
clinical utility are still limited.20-23
More recently, circulating tumor cells (CTCs) isolated
from blood have been tested as a new prognostic tool and
as markers of disease progression.24-42 Using CTCs as a
biomarker affords the advantage of capturing cells that are
biologically relevant to the metastatic process.43,44 CTCs
are a rare population of cells of epithelial origin detectable
in the blood of cancer patients.24,26 The presence of CTCs
in the blood was documented more than a century ago by
T. R. Ashworth, an Austrian pathologist who first reported
this type of cell.45 Through the years, researchers have
used various techniques for isolating CTCs including
microfluidics,46-50
antibody-coated
magnetic
beads
combined with immunohistochemistry (IHC)27,51,52 and
multiplex polymerase chain reaction (PCR).53-55 Using
these techniques, researchers have reported worse
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prognoses with higher CTC counts in patients with
breast,27-29,31,32,34,35,40,54,56-59 colon,25,60,61 prostate30,46,62,63 and
lung cancer.64-67
Currently, CellSearch® (Veridex LLC, Raritan, NJ) is the
only U.S. Food and Drug Administration (FDA)-approved
technique for quantifying CTCs in patients with metastatic
cancer. The CellSearch® isolation is a multistep process
involving an initial CTC enrichment stage using magnetic
particles recognizing the epithelial cell adhesion molecule
(EpCAM). This enrichment concentrates CTCs from 7.5
ml of blood to 300 µl. The cell concentrate is stained for
epithelial cell markers (cytokeratin-8, -18, -19), nucleic acid
dye 4, 2-diamidino-2-phenylindole dihydrochloride (DAPI),
and a leukocyte-specific marker (CD45). The stained cells are
imaged and analyzed using semiautomated image analysis.
In this assay, a CTC is defined as a DAPI positive, cytokeratin
positive and CD45 negative cell. The positive threshold is
set at 5 CTCs per 7.5 ml of blood. The positive selection
using EpCAM-coated ferromagnetic beads enables binding
of multiple ferromagnetic particles to a single cell through
the use of biotin/avidin chemistry, thereby amplifying the
magnetic load. This chemistry increases CTC capture and
sensitivity, but leads to nonspecific binding to leukocytes.
The cell isolate is stained, enabling one to distinguish CTCs
from leukocytes and cell debris.
Independent research has previously validated the analytical
performance of the CellSearch® system.68 The inter- and
intra-assay variability are very low at <5%. Furthermore,
shipping and storage up to 72 hours has minimal effects on
CTC detection, if samples are stored at room temperature.
Longer durations of storage increase unassigned events, cells
requiring identification by the user, and the time required for
analysis. The recovery efficiency of cancer cell lines diluted
in healthy blood is reported to be 80%.68
One limitation of the CellSearch® method is the positive
selection of CTCs using EpCAM-antibody coated beads.
While a significant portion (80%-100%) of breast cancers
express EpCAM,69-71 studies indicate lower EpCAM
expression in CTCs and disseminated tumor cells.72
Furthermore, there is decreased EpCAM expression with
epithelial-mesenchymal transition.73 This suggests that
selection of CTCs based on EpCAM expression may
reduce CTC capture. The avidin/biotin chemistry utilized
by CellSearch® is designed to overcome this decrease in
EpCAM antigen expression by amplifying the magnetic
load per antigen.
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A second weakness of CellSearch® is the use of specific
cytokeratins to identify CTCs. Downregulation of
cytokeratins
occurs
with
epithelial-mesenchymal
74,75
transformation.
The possible reduction in expression of
cytokeratins by CTCs is addressed in CellSearch® by using
pan-cytokeratin antibodies.
In the 2007 American Society for Clinical Oncology (ASCO)20
update of recommendations for tumor biomarkers in breast
cancer, the available evidence for CTC measurements in
patients with advanced breast cancer was reviewed. The
2007 ASCO guidelines recommended against use of CTC
measurements pending further evidence and validations.
However, several studies regarding the role of CTCs as a
prognostic factor or as a marker of disease progression
have been published since the ASCO review. One metaanalysis has addressed the use of PCR-based techniques
for quantifying the presence of CTCs as a biomarker.56
But PCR-based techniques fail to give information on the
morphology and other features of the tumor cells present
in the peripheral blood and there is no FDA-approved
technology for PCR-based techniques (Table 1). No reviews
or meta-analyses have addressed the use of IHC-based CTC
isolation techniques as a marker for patients with metastatic
breast cancer.
Table 1. Advantages and disadvantages of current CTC
isolation techniques

IHC-based

Approach

Advantage

Cell search
CellSearch
CTC chip
Filter-based μCell
concentrator

Cell morphology Multistep
Cell enumeration Positive selection
Multiple stainings
with EpCAM
Localization of
stainings

CK19
Mammoglobin
PCR-based CEA

Multiplex

Disadvantage

High background
Limited to CTC
specific markers
Low cell number
No cell enumeration

CEA, carcinoembryonic antigen; CTC, circulating tumor cell; CK19,
cytokeratin-19; EpCAM, epithelial cell adhesion molecule; IHC,
immunohistochemistry; PCR, polymerase chain reaction.

The current review will serve to summarize published
articles addressing the use of IHC-based CTC isolation as
a marker in patients with metastatic breast cancer. The aim
of this review is to assist medical oncologists and oncology
nurse practitioners in understanding the potential use of
CTCs in clinical practice, and to provide guidance for future
research needs on CTCs as a marker in patients with MBC.

Reviews

Methods

Literature Search
The databases PubMed and Web of Science were
systematically searched for all relevant articles reporting
human studies published from January 2001 to September
2013 (past 12 years). The Medical Subject Headings (MeSH
terms)/keywords used included “circulating tumor cells,”
“neoplastic cells, circulating,” “breast neoplasms” or “breast
cancer,” and “prognostic*” or “outcome*.” Reviewed
publications were limited to articles. The reference list was
checked for relevant articles that contained retrospective or
prospective studies of patients with metastatic breast cancer.
Inclusion and Exclusion Criteria
The search results were then screened according to the
following inclusion criteria: (1) outcome measurements
reported had to include either median progression-free
survival (PFS) or overall survival (OS) or both; (2)
measurements had to include CTC enumeration defined as
EpCAM-positive, DAPI-positive, cytokeratin-positive and
CD45-negative cells; (3) circulating tumor cells had to be
isolated from venous blood.
Articles were excluded if they reported clinical trials
involving patients that received surgery during the course of
the study. The article search for this review did not include
unpublished literature, conference abstracts, or dissertations.
No language restrictions were placed on this search, but
following the initial review of English abstracts, no nonEnglish articles were selected. The references of selected
articles were searched by hand for additional studies, but no
unique publications were identified by this search.
Data Extraction
The first author (FMH) screened and retrieved the literature
list using the mentioned criteria. The reviewer (FMH) was not
blinded to the article title or authors. The data extracted from
each article included CTC characteristics, median PFS, and
OS. Within the selected articles, radiologists were blinded
to the patient clinical progression and CTC characteristics.
Data Analysis
The selected studies were assessed unblinded by the authors
using the critical appraisal of prognostic test questionnaire
from the Center for Evidence Based Medicine (CEBM) at
University of Oxford (www.cebm.net). The critical appraisal
questionnaire does not provide a numeric score, but it contains
a set of questions appraising the validity of the clinical trial,
with three possible answer options, “yes,” “no” or “unclear.”
An article was included in this review if reviewers answered
Reviews

“no” or “unclear” to only one CEBM appraisal question and
“yes” to all other appraisal questions (Table 2). Since the
study appraisal did not provide a numeric value, intrarater
reliabilities were not analyzed.
Statistical Analysis
We recorded the reported median and Cox hazard ratio values
for PFS and OS, in addition to their 95% confidence intervals.

Results

The current review only included clinical studies that
reported PFS, OS, or both in patients with MBC. The
initial search with “breast neoplasms” and “neoplastic cells,
circulating” or other keywords representing breast cancer and
CTCs produced a broad selection of articles from PubMed
and Web of Science. The additional keywords “outcome*”
and “prognosis*” were added, producing 164 articles from
PubMed and 41 from Web of Science (searched in September
2013). After further screening of the abstracts, 17 articles
were selected based on the inclusion and exclusion criteria.
The main reason for exclusion included: studies involving
patients with nonmetastatic breast cancer, clinical trials using
non-IHC based CTC isolation, and studies not reporting PFS
or OS. From the selected articles, none were exluded based
on their CEBM questionnaire.
All of the selected articles with the exception of one
study used the FDA-approved CellSearch® technique for
isolating CTCs (Table 2). While other approaches have
been developed and tested in research settings, the articles
reporting these techniques did not meet the inclusion and
exclusion criteria for this review. Gradilone et al.54 reported
the only study implementing a different CTC identification
method. This study used magnetic bead selection coupled
with multiplex PCR to study CTC gene expression of
chemotherapy resistance proteins.
Studies using CellSearch® to enumerate CTCs reported
differences in median PFS or OS at the cut-off of
5 CTCs/7.5 mL blood (Tables 3 and 4).27,29,31,32,34,35,57,76-80 All
studies reported decreased OS of CTC-positive versus CTCnegative patients. These reported measurements included
changes in median OS and the Cox proportional hazard
ratio. A subset of the selected trials reported lower median
PFS between CTC-positive and CTC-negative patients.
One study reported a significant difference in OS between
the CTC-positive and CTC-negative patients, but reported
a limited difference in PFS.76 The inconsistency of OS and
PFS in this trial may be due to the limitations of PFS as a
marker for OS.
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Table 2. Summary of reviewed studies, isolation method and review based on Oxford prognostic checklist
Author
Cristofanilli et al.27
Budd et al.35
Hayes et al. 29
Cristofanilli et al. 57

Year
2004
2006
2006
2007

# of participants
177
138
177
151

Method
Prospective
Prospective
Prospective
Retrospective

Follow-up time
9 months
Median 28 months
30 months
Median 12.7 months

Isolation method
CellSearch
CellSearch
CellSearch
CellSearch

Median 8.8 months

Oxf Prog checklist
All yes
All yes
All yes
Yes, except patient
stage at enrollment
is not mentioned
All yes
Yes, no separation
of other prognostic
groups
Yes, no separation
of other prognostic
groups
All yes

Nole et al. 41
De Giorgi et al. 31

2008
2009

60
115

Prospective
Retrospective

Median 34 weeks
40 months after midtherapy

Liu et al. 34

2009

81

Prospective

Median 13.3

Bidard et al. 37

2010

Prospective

De Giorgi et al. 32
Botteri et al. 59
Gradilone et al. 54

2010
2010
2011

67 patients
(4 nonoperable
locoregional
relapse)
195
80
42

Retrospective
Prospective
Prospective

36 months
Median 28 months
Median 24 months

All yes
All yes
All yes

58

Retrospective

Median 13.2 months

235
253
267
517
486

Retrospective
Prospective
Prospective
Retrospective
Prospective

Median 18 months
Median 11 months
Median 14.9 months
Median 24.6 months
Median 11.1 months

Yes, except no
separation of
different prognostic
determinants
All yes
All yes
All yes
All yes
All yes

CellSearch
CellSearch
EpCAM-coated
beads (CELLection
Dynabeads) +
Multiplex PCR
CellSearch

Harkopf et al. 36

2011

Giuliano et al. 33
Muller at al. 76
Pierga et al. 80
Giordana et al. 77
Wallwiener et al. 79

2011
2011
2012
2012
2013

CellSearch
CellSearch
CellSearch
CellSearch

CellSearch
CellSearch
CellSearch
CellSearch
CellSearch

EpCAM, epithelial cell adhesion molecule; PCR, polymerase chain reaction.

Several studies compared CTC counts with imaging
modalities including fluorodeoxyglucose positron emission
tomography (PET) and computed tomography (CT) imaging.
Multivariate analysis of CTC enumerations indicated
that CTCs provide additional prognostic information that
is unavailable with imaging studies.29,32,57 Furthermore,
baseline CTC enumeration better predicted median OS
compared to PET-based techniques.31 Interestingly, the CTC
counts were dependent on the site of metastasis, in addition
to the the level of metastatic involvement. For example,
patients with bone and visceral metastases had higher CTC
counts compared to patients with bone-only metastasis.32
Most studies did not control for type of anticancer therapy.
The therapies used in the reviewed articles included various
endocrine therapies targeting the hormone receptors, agents
targeting the HER2 and vascular endothelial growth factor
receptors, and traditional chemotherapy. In one reviewed
88
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study,37 the cut-off of 3 CTCs per 7.5 ml of blood was
associated with a shorter time-to-disease-progression in
patients with MBC receiving the antiangiogenic drug
bevacizumab.37 Angiogenesis is a necessary step for
intravasation of CTCs into the blood; therefore, the lower
cut-off in this study for CTC-positive samples may be due to
the impairment of angiogenesis by bevacizumab. The ability
of CTCs to predict a prognosis, independent of patient
therapy, further supports their use as a biomarker.
In addition, multiple trials evaluated CTCs at specific study
intervals, and reported significant differences in outcomes
based on CTC status changes during treatment, suggesting
the role of CTCs as a marker of disease progression. Hayes
et al. reported similar median OS between baseline CTC
negative participants and patients that converted from CTC
positive to CTC negative during the study.29 Furthermore,
all studies reported that in response to therapy, there was a
Reviews

Table 3. Median progression free survival (PFS) values for CTC-positive and CTC-negative patients, and Cox proportional hazard
ratios (HR) based on univariate analysis
Author

Year

Cristofanilli27
Nole41
Liu34
Gradilone54
Giuliano33
Muller76
Pierga80
Giordano77
Wallwiener79

2004
2008
2009
2011
2011
2011
2012
2012
2013

Median PFS
CTC<5, CTC≥5 (month)
7.0, 2.7
>11.5, 5.1
5.1, 3.2
16.3, 9.2
12.0, 7.0
10.9, 9.3
16.0, 8.2
6.3, 5.8
7.6, 4.8

95% CI PFS
CTC<5, CTC≥5 (month)
(5.8-8.9),(2.1-4.4)
N/A
(3.1-6.7),(2.5-6.2)
N/A
(9.6-14.3),(5.8-8.2)
(9.4-12.5),(7.8-10.9)
N/A
(5.3-7.3),(5.0-6.7)
(5.9-9.3),(3.9-5.6)

Cox HR
1.76
2.5
1.4
N/A
1.72
N/A
1.9
1.23
1.82

CI: confidence interval; CTC: circulating tumor cell.

Table 4. Median overall survival (OS) for CTC-positive and CTC-negative patients, and Cox proportional hazard ratio (HR) based
on univariate analysis
Author

Year

Cristofanilli27
Budd35
Hayes29
Cristofanilli57
De Giorgi31
De Giorgi32
Hartkopft36
Giuliano33
Muller76
Piergra80
Giordano77
Wallwiener79

2004
2006
2006
2007
2009
2010
2011
2011
2011
2012
2012
2013

Median OS
CTC<5, CTC≥5 (month)
>18, 10.1
22.6, 8.5
21.9, 10.9
29.3, 13.5
28.0, 6.2
34.8, 18.5
>24, 9.8
40.1, 21.9
20.1, 14.0
>33, 19.8
32.4, 18.3
>23, 18.01

95% CI OS
CTC<5, CTC≥5 (month)
N/A,(6.2-14.6)
(20.1 to >25.0),(6.2-15.1)
(20.1 to >25),(6.4-15.1)
N/A
(17.2 to >18.2), (5.9-15.7)
(23.5 to >40),(13.6-85.0)
N/A, (7.3-12.3)
(34.9-45.4),(15.6-28.4)
(18.8-21.5),(12.8-21.5)
N/A
(25.3-39.5),(15.5-21.1)
N/A

Cox HR

95% CI (Cox HR)

4.26
3.18
2.45
2.3
1.3
2.2
N/A
2.5
2.48
2.4
2.1
4.8

N/A
(2.0-5.9)
(1.6-3.7)
(1.3-4.1)
(0.7-2.6)
(1.4-3.5)
N/A
(1.6-3.9)
(1.5-4.4)
(1.1-5.4)
(1.7-2.7)
(2.9-7.8)

CI: confidence interval; CTC: circulating tumor cell.

significant drop in absolute CTC counts and the number of
CTC positive patients.27,31,36 Based on these earlier results, a
clinical trial was initiated by the Southwest Oncology Group
(SWOG S0500; NCT00382018, www.clinicaltrials.gov) to
test whether women with MBC and with elevated CTCs
after one course of first-line chemotherapy would benefit
from a switch in chemotherapy. This would differ from the
current clinical standards, because the switch in therapy
would occur prior to identifiable clinical progression based
on standard clinical or imaging criteria. The preliminary
results of this trial have now been reported and the primary
endpoint of improved median OS was not met.81 In addition
to the SWOG trial, a second trial (CirCè01) has been
initiated to further characterize the role of CTCs as predictive
markers of response to therapy. The CirCè01 is a phase III
multicenter clinical trial using changes in CTC counts to
Reviews

guide the choice of third-line chemotherapy for MBC. In
this trial, CTCs will be measured prior to the addition of a
new chemotherapy drug and, if there is little change in CTC
counts after two weeks, a new chemotherapy will be initiated
(NCT01349842). The final results from these trials will serve
to determine the utility of changes in CTC enumeration on
guiding patient therapy, and will better establish the role of
CTCs in clinical practice.

Conclusion

The discovery of circulating tumor cells and the development
of different isolation methods has led to an expanding area
of research. The prognostic value of baseline CTCs using the
Veridex method at the defined 5 cells/mL cutoff in metastatic
breast cancer is clear. Published studies have correlated
CTC counts with MBC to tumor burden, PET and CT-based
Aurora.org/Journal
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staging, site of metastasis, level of metastatic involvement,
OS and PFS.
Despite the prognostic significance of CTCs, their role as a
predictive marker remains unknown. Randomized, controlled
clinical trials that include therapeutic arms dependent on
changes in CTC enumeration are required to establish the
usefulness of this biomarker in managing patient care. The
final results of the SWOG-S0500 and CirCè01 trials will
serve to establish the role of CTCs as markers for quantifying
disease response to therapy. At this time, routine clinical use
as a predictive marker is not recommended.
An advantage of IHC-based CTC isolation techniques is
the ability to quantify the expression and activity of specific
biologic receptors. For example, some previous studies
have quantified HER2, estrogen-receptor and progesteronereceptor expression in CTCs.82 It would be important to
correlate the biomolecular characteristics of CTCs with
patient outcome, and to utilize this information for designing
therapeutic trials. A recently initiated clinical trial (DETECT
III) plans to use CTC HER2 status in patients with metastatic
breast cancer to guide therapy. In this trial, patients with
HER2-negative tumor but HER2-positive CTCs will
receive lapatinib with standard therapy or standard therapy
alone. The estimated primary completion date for this trial
is March 2016 with the primary outcome measure of PFS
(NCT01619111). This trial will determine the utility of CTC
biomolecular signatures for guiding patient therapy.
CTC analysis is limited by the availability of current isolation
technologies and their cost. The development of other CTC
isolation techniques including PCR and microfluidic-based
methods can address these shortcomings.46-48,50,56,83 The ability
to isolate CTCs at multiple points of treatment by simple
blood draw is an important advantage of CTCs in comparison
to biopsy and imaging techniques. Currently, various tumor
markers, for example, CEA, CA15-3 and CA27.29, are
used to assess response to therapy. The addition of CTC
enumeration to a panel that includes these tumor markers can
increase their overall sensitivity and specificity. Compared
to the tumor markers, CTCs can potentially provide multiple
biological measurements including expression of hormone
receptors, HER2, insulin growth factor receptor, and the
receptors kinase activity. To better measure these biological
markers in a single CTC, further advances in single-cell
analysis are required. This would fulfill the promise of CTC
as a “liquid biopsy” of the tumor. But even with the evidence
supporting the role of CTCs as a marker of disease, there are
a subset of CTC negative MBC patients with poor outcomes.
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Therefore, further research is required to understand the
limitations of CTCs as a biomarker of disease progression.
In conjunction with clinical trials, controlled biologic
experiments are required to establish the relevance of CTCs
to disease spread.
Treatment of patients with metastatic breast cancer requires
a fine balance between administering therapies to control
the malignancy with the goal of improving cancer-related
symptoms and complications as well as survival, but at
the same time limiting the negative impact on quality of
life from the treatments. Often, clinicians are faced with
the challenge of determining whether the treatment is
benefiting the patient using limiting information derived
from the patient’s symptoms, exam and basic laboratory
results. Newer tools are clearly needed to aid in this decision
making. Circulating tumor cells have the potential to be a
noninvasive, early predictive biomarker to aid clinicians
in their goal of maximizing benefit and limiting harms to
patients with advanced breast cancer in the future.
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